title: ACS chemical neuroscience molecule spotlight on BMS-708163.
abstract: BMS-708163 is a novel, sulfonamide containing γ-secretase inhibitor from Bristol-Myers Squibb Co. currently in Phase II clinical trials for the treatment of Alzheimer's disease (AD).
authors.affiliation: Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University, Vanderbilt University Medical Center, Department of Pharmacology and Chemistry, Nashville, Tennessee 37232-6600, USA.
authors.forename: Corey R
authors.initials: CR
authors.lastname: Hopkins
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy / Q000201:enzymology; D053829:Amyloid Precursor Protein Secretases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D000818:Animals; D017322:Clinical Trials, Phase II as Topic / Q000639:trends; D055808:Drug Discovery / Q000639:trends; D006801:Humans; D009488:Neurosciences; D010069:Oxadiazoles / Q000737:chemistry* / Q000494:pharmacology / Q000627:therapeutic use*; D012958:Societies, Scientific; D013449:Sulfonamides / Q000737:chemistry* / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: C554092:BMS 708163; D010069:Oxadiazoles; D013449:Sulfonamides; D053829:Amyloid Precursor Protein Secretases